Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cesium-131 Brachytherapy in Recurrent Head and Neck Cancer
NCT02467738Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2015
- Primary completion
- May 2020
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cesium-131 in head and neck carcinoma (HNC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Disease free survival at 24 months and Incidence of toxicity at 90 days. Started Mar 2015; status: completed.
02
Drugs
cesium-131
03
Conditions
head and neck carcinoma (HNC)
Beyond the preview
Go deeper on NCT02467738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02467738.